Second drug attempts to rescue weaker CAR-T results in blood cancer

NCT ID NCT06523621

Recruiting now Disease control Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding the immunotherapy drug nivolumab can improve treatment outcomes for patients with hard-to-treat multiple myeloma. The trial focuses on 50 patients whose cancer did not respond well enough to a specialized CAR-T cell therapy called idecabtagene vicleucel. Researchers will give nivolumab to see if it helps the CAR-T cells work better and leads to deeper cancer remission.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Atrium Health Wake Forest Baptist Comprehensive Cancer Center
RECRUITING

Winston-Salem, North Carolina, 27103, United States

Contact

Contact Email: •••••@•••••
Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28204, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA